Cargando…
A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, an...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965204/ https://www.ncbi.nlm.nih.gov/pubmed/36851102 http://dx.doi.org/10.3390/vaccines11020224 |
_version_ | 1784896699610693632 |
---|---|
author | Mohammed, Hassen Pham-Tran, Dan Duy Yeoh, Zi Yi Michelle Wang, Bing McMillan, Mark Andraweera, Prabha H. Marshall, Helen S. |
author_facet | Mohammed, Hassen Pham-Tran, Dan Duy Yeoh, Zi Yi Michelle Wang, Bing McMillan, Mark Andraweera, Prabha H. Marshall, Helen S. |
author_sort | Mohammed, Hassen |
collection | PubMed |
description | Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, and severe outcomes. We systematically searched literature up to 1 August 2022. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled vaccine effectiveness (VE). Overall, 28 studies were included representing 11 million individuals. The pooled VE against Omicron infection was 20.4% (95%CI: 12.1–28.7%) and 23.4% (95%CI: 13.5–33.3%) against symptomatic infection with variation based on vaccine type and age groups. VE sharply declined from 28.1% (95%CI: 19.1–37.1%) at three months to 3.9% (95%CI: −24.8–32.7%) at six months. Similar trends were observed for symptomatic Omicron infection. A booster dose restored protection against Omicron infection up to 51.1% (95%CI: 43.8–58.3%) and 57.3% (95%CI: 54.0–60.5%) against symptomatic infection within three months; however, this waned to 32.8% (95%CI: 16.8–48.7%) within six months. VE against severe Omicron infection following the primary course was 63.6% (95%CI: 57.5–69.7%) at three months, decreased to 49% (95%CI: 35.7–63.4%) within six months, and increased to 86% after the first or second booster dose. |
format | Online Article Text |
id | pubmed-9965204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99652042023-02-26 A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) Mohammed, Hassen Pham-Tran, Dan Duy Yeoh, Zi Yi Michelle Wang, Bing McMillan, Mark Andraweera, Prabha H. Marshall, Helen S. Vaccines (Basel) Systematic Review Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, and severe outcomes. We systematically searched literature up to 1 August 2022. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled vaccine effectiveness (VE). Overall, 28 studies were included representing 11 million individuals. The pooled VE against Omicron infection was 20.4% (95%CI: 12.1–28.7%) and 23.4% (95%CI: 13.5–33.3%) against symptomatic infection with variation based on vaccine type and age groups. VE sharply declined from 28.1% (95%CI: 19.1–37.1%) at three months to 3.9% (95%CI: −24.8–32.7%) at six months. Similar trends were observed for symptomatic Omicron infection. A booster dose restored protection against Omicron infection up to 51.1% (95%CI: 43.8–58.3%) and 57.3% (95%CI: 54.0–60.5%) against symptomatic infection within three months; however, this waned to 32.8% (95%CI: 16.8–48.7%) within six months. VE against severe Omicron infection following the primary course was 63.6% (95%CI: 57.5–69.7%) at three months, decreased to 49% (95%CI: 35.7–63.4%) within six months, and increased to 86% after the first or second booster dose. MDPI 2023-01-19 /pmc/articles/PMC9965204/ /pubmed/36851102 http://dx.doi.org/10.3390/vaccines11020224 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Mohammed, Hassen Pham-Tran, Dan Duy Yeoh, Zi Yi Michelle Wang, Bing McMillan, Mark Andraweera, Prabha H. Marshall, Helen S. A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
title | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
title_full | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
title_fullStr | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
title_full_unstemmed | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
title_short | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
title_sort | systematic review and meta-analysis on the real-world effectiveness of covid-19 vaccines against infection, symptomatic and severe covid-19 disease caused by the omicron variant (b.1.1.529) |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965204/ https://www.ncbi.nlm.nih.gov/pubmed/36851102 http://dx.doi.org/10.3390/vaccines11020224 |
work_keys_str_mv | AT mohammedhassen asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT phamtrandanduy asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT yeohziyimichelle asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT wangbing asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT mcmillanmark asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT andraweeraprabhah asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT marshallhelens asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT mohammedhassen systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT phamtrandanduy systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT yeohziyimichelle systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT wangbing systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT mcmillanmark systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT andraweeraprabhah systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT marshallhelens systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 |